High Free Cash Flow Stocks
COLL is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Price & Overview
NASDAQ:COLL • US19459J1043
Current stock price
32.31 USD
-0.94 (-2.83%)
At close:
32.31 USD
0 (0%)
After Hours:
The current stock price of COLL is 32.31 USD. Today COLL is down by -2.83%. In the past month the price decreased by -13.33%. In the past year, price increased by 14.82%.
COLL Key Statistics
52-Week Range23.23 - 50.7866
Current COLL stock price positioned within its 52-week range.
1-Month Range31.8401 - 37.76
Current COLL stock price positioned within its 1-month range.
- Market Cap
- 1.026B
- P/E
- 4.33
- Fwd P/E
- 4.24
- EPS (TTM)
- 7.46
- Dividend Yield
- N/A
COLL Stock Performance
Today
-2.83%
1 Week
-3.32%
1 Month
-13.33%
3 Months
-29.04%
Longer-term
6 Months -6.65%
1 Year +14.82%
2 Years -12.51%
3 Years +38.85%
5 Years +44.89%
10 Years +69.52%
COLL Stock Chart
COLL Stock Screens
COLL currently appears in the following ChartMill screener lists.
RSI Oversold Stocks
COLL is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
COLL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is a bad performer in the overall market: 77.4% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
COLL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to COLL. COLL has an excellent profitability rating, but there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
COLL Earnings
On February 26, 2026 COLL reported an EPS of 2.04 and a revenue of 205.45M. The company missed EPS expectations (-14.08% surprise) and missed revenue expectations (-2.39% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$2.04
Revenue Reported205.449M
EPS Surprise -14.08%
Revenue Surprise -2.39%
COLL Forecast & Estimates
12 analysts have analysed COLL and the average price target is 55.25 USD. This implies a price increase of 71% is expected in the next year compared to the current price of 32.31.
For the next year, analysts expect an EPS growth of 2.08% and a revenue growth 3.76% for COLL
Analysts
Analysts81.67
Price Target55.25 (71%)
EPS Next Y2.08%
Revenue Next Year3.76%
COLL Groups
Sector & Classification
COLL Financial Highlights
Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 7.46. The EPS increased by 15.66% compared to the year before.
Income Statements
Revenue(TTM)780.57M
Net Income(TTM)62.87M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.05% | ||
| ROA | 3.79% | ||
| ROE | 20.84% | ||
| Debt/Equity | 2.59 |
Chartmill High Growth Momentum
EPS Q2Q%15.25%
Sales Q2Q%12.92%
EPS 1Y (TTM)15.66%
Revenue 1Y (TTM)23.62%
COLL Ownership
Ownership
Inst Owners122.15%
Shares31.75M
Float31.05M
Ins Owners2%
Short Float %13.78%
Short Ratio8.48
COLL Latest News, Press Relases and Analysis
6 days ago - By: Chartmill
COLL Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.764B | ||
| PFE | PFIZER INC | 9.48 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 125.711B | ||
| ZTS | ZOETIS INC | 16.66 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 27.972B | ||
| VTRS | VIATRIS INC | 5.36 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About COLL
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 423 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Company Info
IPO: 2015-05-07
COLLEGIUM PHARMACEUTICAL INC
100 Technology Center Dr
Stoughton MASSACHUSETTS 02072 US
CEO: Joseph Ciaffoni
Employees: 357
Phone: 17817133699
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What does COLLEGIUM PHARMACEUTICAL INC do?
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 423 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
What is the current price of COLL stock?
The current stock price of COLL is 32.31 USD. The price decreased by -2.83% in the last trading session.
Does COLLEGIUM PHARMACEUTICAL INC pay dividends?
COLL does not pay a dividend.
What is the ChartMill technical and fundamental rating of COLL stock?
COLL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists COLL stock?
COLL stock is listed on the Nasdaq exchange.
Is COLLEGIUM PHARMACEUTICAL INC (COLL) expected to grow?
The Revenue of COLLEGIUM PHARMACEUTICAL INC (COLL) is expected to grow by 3.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.